Biomea Fusion’s icovamenib achieved a mean HbA1c reduction of 0.5% in Arm B after 12 weeks of 100mg QD dosing (p=0.012). Severe insulin-deficient diabetes (SIDD) patients saw the best results in Arm B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback